Stephen F Little

Summary

Affiliation: Walter Reed Army Medical Center
Country: USA

Publications

  1. ncbi Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine
    S F Little
    United States Army Medical Research Institute of Infectious Diseases, Bacteriology Division, 1425 Porter Street, Fort Detrick, Frederick, MD 21702 5033, USA
    Vaccine 25:2771-7. 2007
  2. ncbi Anthrax vaccines: a development update
    Stephen F Little
    United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA
    BioDrugs 19:233-45. 2005
  3. ncbi Evaluation of an anti-rPA IgG ELISA for measuring the antibody response in mice
    S F Little
    United States Army Medical Research Institute of Infectious Disease, Bacteriology Division, 1425 Porter Street, Fort Detrick, Frederick, MD 21702 5011, USA
    Biologicals 32:62-9. 2004
  4. ncbi Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine
    S F Little
    United States Army Medical Research Institute of Infectious Diseases, Bacteriology Division, 1425 Porter Street, Fort Detrick, Frederick, MD 21702 5033, USA
    Vaccine 24:2530-6. 2006
  5. ncbi Monoclonal antibodies directed against protective antigen of Bacillus anthracis enhance lethal toxin activity in vivo
    Stephen F Little
    Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
    FEMS Immunol Med Microbiol 62:11-22. 2011
  6. ncbi Evaluation of quantitative anti-F1 IgG and anti-V IgG ELISAs for use as an in vitro-based potency assay of plague vaccine in mice
    S F Little
    United States Army Medical Research Institute of Infectious Disease, Bacteriology Division, 1425 Porter Street, Fort Detrick, MD 21702 5011, USA
    Biologicals 36:287-95. 2008
  7. ncbi Development of an in vitro-based potency assay for anthrax vaccine
    S F Little
    United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702 5033, USA
    Vaccine 22:2843-52. 2004
  8. ncbi Western blot analysis of the exotoxin components from Bacillus anthracis separated by isoelectric focusing gel electrophoresis
    Stephen F Little
    Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702 5011, USA
    Biochem Biophys Res Commun 317:294-300. 2004
  9. ncbi Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine
    S F Little
    Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702 5011, USA
    Vaccine 22:422-30. 2004
  10. ncbi Quantitative anti-F1 and anti-V IgG ELISAs as serological correlates of protection against plague in female Swiss Webster mice
    S F Little
    Bacteriology Division, United States Army Medical Research Institute of Infectious Disease USAMRIID, Fort Detrick, Frederick, MD 21702, USA
    Vaccine 28:934-9. 2010

Collaborators

Detail Information

Publications21

  1. ncbi Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine
    S F Little
    United States Army Medical Research Institute of Infectious Diseases, Bacteriology Division, 1425 Porter Street, Fort Detrick, Frederick, MD 21702 5033, USA
    Vaccine 25:2771-7. 2007
    ..However, differences in short-term efficacy were not observed...
  2. ncbi Anthrax vaccines: a development update
    Stephen F Little
    United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, USA
    BioDrugs 19:233-45. 2005
    ..This review summarizes the work of numerous laboratories in the search for alternative vaccines against anthrax that are well tolerated, provide long-lasting immunity, and are efficacious...
  3. ncbi Evaluation of an anti-rPA IgG ELISA for measuring the antibody response in mice
    S F Little
    United States Army Medical Research Institute of Infectious Disease, Bacteriology Division, 1425 Porter Street, Fort Detrick, Frederick, MD 21702 5011, USA
    Biologicals 32:62-9. 2004
    ....
  4. ncbi Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine
    S F Little
    United States Army Medical Research Institute of Infectious Diseases, Bacteriology Division, 1425 Porter Street, Fort Detrick, Frederick, MD 21702 5033, USA
    Vaccine 24:2530-6. 2006
    ..Neither gender nor challenge dose were identified as having a statistically significant effect on survival. Booster vaccinations with rPA may be required for the long-term protection of rabbits against anthrax...
  5. ncbi Monoclonal antibodies directed against protective antigen of Bacillus anthracis enhance lethal toxin activity in vivo
    Stephen F Little
    Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA
    FEMS Immunol Med Microbiol 62:11-22. 2011
    ..This is the first demonstration that PA mAbs can enhance LeTx intoxication in vivo...
  6. ncbi Evaluation of quantitative anti-F1 IgG and anti-V IgG ELISAs for use as an in vitro-based potency assay of plague vaccine in mice
    S F Little
    United States Army Medical Research Institute of Infectious Disease, Bacteriology Division, 1425 Porter Street, Fort Detrick, MD 21702 5011, USA
    Biologicals 36:287-95. 2008
    ....
  7. ncbi Development of an in vitro-based potency assay for anthrax vaccine
    S F Little
    United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702 5033, USA
    Vaccine 22:2843-52. 2004
    ..An advantage of the proposed in vitro-based potency assay is that it will not need stringent biosafety containment measures as required by the current guinea pig potency assay...
  8. ncbi Western blot analysis of the exotoxin components from Bacillus anthracis separated by isoelectric focusing gel electrophoresis
    Stephen F Little
    Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, MD 21702 5011, USA
    Biochem Biophys Res Commun 317:294-300. 2004
    ..anthracis by determining the isoelectric points of the exotoxin components and may be useful in the development of protective vaccines against B. anthracis infection...
  9. ncbi Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine
    S F Little
    Bacteriology Division, United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702 5011, USA
    Vaccine 22:422-30. 2004
    ..0015) of protection against a B. anthracis aerosol spore challenge in rabbits...
  10. ncbi Quantitative anti-F1 and anti-V IgG ELISAs as serological correlates of protection against plague in female Swiss Webster mice
    S F Little
    Bacteriology Division, United States Army Medical Research Institute of Infectious Disease USAMRIID, Fort Detrick, Frederick, MD 21702, USA
    Vaccine 28:934-9. 2010
    ..7-fold (p=0.0051) and 2.5-fold (p=0.0054) increase in odds of survival, respectively, against either bubonic or pneumonic plague and may serve as serological correlates of protection...
  11. ncbi Advances in the development of next-generation anthrax vaccines
    Arthur M Friedlander
    United States Army Medical Research Institute of Infectious Diseases, Headquarters, 1425 Porter Street, Fort Detrick, MD 21702 5011, USA
    Vaccine 27:D28-32. 2009
    ..Attempts to broaden the protection afforded by PA-based vaccines have focused on adding other B. anthracis components, including spore and capsule antigens...
  12. ncbi Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants
    Scott Jendrek
    Building 320, SAIC Frederick Inc, National Cancer Institute, Frederick Cancer Research and Development Center, Frederick, MD 21702, USA
    Vaccine 21:3011-8. 2003
    ..These data suggest that the interaction between rPA and aluminum hydroxide adjuvant is predominantly electrostatic in character...
  13. ncbi Anthrax capsule vaccine protects against experimental infection
    Donald J Chabot
    US Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Frederick, MD 21701, USA
    Vaccine 23:43-7. 2004
    ..Surprisingly, some protection was also observed when protective antigen was conjugated to itself...
  14. ncbi An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals
    John F Hewetson
    United States Army Medical Research Institute of Infections Diseases USAMRIID, Fort Detrick, MD 21702, United States
    Vaccine 26:4262-6. 2008
    ..This analytical method may provide additional opportunities to compare the efficacy of improved anthrax vaccines with the licensed vaccine...
  15. ncbi Mapping of antibody responses to the protective antigen of Bacillus anthracis by flow cytometric analysis
    Douglas S Reed
    Division of Toxinology and Aerobiology, U S Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702 5011, USA
    Cytometry 49:1-7. 2002
    ..Knowledge of the target and functional capability of the antibody response against an antigen provides more specific and relevant information about protective immunity than measuring the total amount of antibody produced against an antigen...
  16. ncbi Anthrax biosensor, protective antigen ion channel asymmetric blockade
    Kelly M Halverson
    United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, Maryland 21702-5011, USA
    J Biol Chem 280:34056-62. 2005
    ..The latter two results suggest the potential application of PA63 nanopore-based biosensors in anthrax therapeutics and diagnostics...
  17. ncbi Bacillus anthracis edema toxin inhibits Staphylococcus aureus enterotoxin B effects in vitro: a potential protein therapeutic?
    Teresa Krakauer
    Integrated Toxicology, US Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland 21702 5011, USA
    Infect Immun 73:7069-73. 2005
    ..Overall, these results suggest a novel use of B. anthracis edema toxin against a bacterial superantigen...
  18. ncbi Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity
    Laura Vitale
    Medarex, Inc, Bloomsbury, New Jersey 08804, USA
    Infect Immun 74:5840-7. 2006
    ....
  19. ncbi Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages
    Nehal Mohamed
    Elusys Therapeutics, Inc, Pine Brook, New Jersey 07058, USA
    Infect Immun 72:3276-83. 2004
    ..The additional significance of these results is that, at least in mice, immunization with PA appears to elicit a poly-clonal response that has a significant prevalence of MAbs that enhance LeTx-mediated killing in macrophages...
  20. ncbi Low doses of antigen coupled to anti-CR2 mAbs induce rapid and enduring IgG immune responses in mice and in cynomolgus monkeys
    Emily C Whipple
    Department of Biochemistry and Molecular Genetics, University of Virginia Health Sciences Center, Charlottesville, VA 22908, United States
    Mol Immunol 44:377-88. 2007
    ..Taken together, these results demonstrate the efficacy of using anti-CR2 mAbs as antigen carriers for i.v. immunization with small amounts of antigens without adjuvant...
  21. ncbi CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques
    Dennis M Klinman
    Section of Retroviral Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bldg 29A, Rm 3 D 10, Bethesda, MD 20892, USA
    Vaccine 22:2881-6. 2004
    ..The ability of CpG ODN to accelerate and magnify the immune response to AVA suggests this strategy may contribute to the development of prophylactic and therapeutic vaccines against biothreat pathogens...